Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

TA117 Hyperparathyroidism - cinacalcet: review decision - July 2013 information

TA117 Hyperparathyroidism - cinacalcet: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 101 KB)

TA117 Hyperparathyroidism - cinacalcet: review proposal - April 2013 information

TA117 Hyperparathyroidism - cinacalcet: Appendix A - provisional matrix of stakeholders (PDF 37 KB)

TA117 Hyperparathyroidism - cinacalcet: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 342 KB)

Review decision - May 2010 information

Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 52 KB)

TA117 Hyperparathyroidism - cinacalcet: review proposal - February 2010 information

A full list of the organisations contacted for this review (PDF 31 KB)

Proposal paper considered by the Institute's Guidance Executive (PDF 59 KB)

Hyperparathroidsom - cinaclacet: Final Appraisal Determination information

Final Appraisal Determination: Hyperparathyoidism (PDF 74 KB)

Response to consultee and commentator comments on the ACD (PDF 59 KB)

Consultee and commentator comments on the ACD

Welsh Assembly Government (PDF 31 KB)

North Eastern Derbyshire PCT letter (PDF 26 KB)

North Eastern Derbyshire PCT (PDF 29 KB)

Department of Health (PDF 30 KB)

Royal College of Physicians (PDF 39 KB)

Royal College of Pathologists (PDF 46 KB)

Renal Association (PDF 28 KB)

National Kidney Research Fund (PDF 67 KB)

British Renal Society (PDF 29 KB)

National Kidney Federation (PDF 77 KB)

Kidney Alliance (PDF 47 KB)

Amgen (PDF 45 KB)

NHS Quality Improvement Scotland (PDF 27 KB)

Hyperparathyroidism - cinacalcet HCl, second appraisal consultation

Hyperparathyroidism - cinacalcet HCI, Second Appraisal Consultation Document information

Response to consultee and comentator comments on the first ACD (PDF 159 KB)

Response to public and web comments on the first ACD (PDF 39 KB)

Expert comments on the first ACD

Payne (PDF 19 KB)

Gittoes (PDF 21 KB)

Consultee and commentator comments on the first ACD

Welsh Assembly Government (PDF 84 KB)

North East Derbyshire Primary Care Trust (PDF 22 KB)

Royal College of Pathologists (PDF 32 KB)

Royal College of Nursing (PDF 23 KB)

Renal Association (PDF 21 KB)

British Renal Society (PDF 21 KB)

Kidney Alliance (PDF 17 KB)

Amgen (PDF 211 KB)

NHS Quality Improvement Scotland (PDF 29 KB)

Hyperparathyroidism - cinacalcet HCl, first appraisal consultation

Hyperparathyroidism - cinacalcet HCI, First Appraisal Consultation Document information

Hyperparathyroidism - cinacalcet HCI, Overview (PDF 154 KB)

Hyperparathyroidism - cinacalcet HCI, Assessment report (PDF 1.66 MB)

Expert written personal statements

Steve Rowe (PDF 41 KB)

Chris Payne (PDF 22 KB)

Alastair Hutchison (PDF 28 KB)

Neil Gittoes (PDF 23 KB)

Amgen Executive Summary (PDF 242 KB)

Non manufacturer submissions

UK Renal Pharmacy Group (PDF 148 KB)

Society for Endocrinology (PDF 309 KB)

Royal College of Physicians (PDF 38 KB)

Royal College of Physicians - cover letter (PDF 29 KB)

Royal College of Nursing (2) (PDF 54 KB)

Royal College of Nursing (1) (PDF 20 KB)

Renal Association (PDF 42 KB)

National Kidney Federation (PDF 123 KB)

Kidney Research UK (PDF 195 KB)

British Renal Society (PDF 86 KB)

Consultee and commentator comments on the assessment report

Welsh Assembly Government (PDF 34 KB)

Royal College of Physicans (PDF 38 KB)

Royal College of Pathologists (PDF 57 KB)

Royal College of Nursing (1) (PDF 20 KB)

NHS Quality Improvement Scotland (PDF 20 KB)

Amgen Ltd (PDF 210 KB)

Amgen Ltd - covering letter (PDF 31 KB)

Hyperparathyroidism - cinacalcet HCl, Final protocol (PDF 134 KB)

Hyperparathyroidism - cinacalcet HCl, Final scope (PDF 33 KB)

Hyperparathyroidism - cinacalcet HCl, Summary of Consultee and commentator comments on the draft scope (PDF 41 KB)

Hyperparathyroidism - cinacalcet HCl, Summary of Consultee and commentator comments on the draft matrix (PDF 43 KB)

(Archive): Hyperparathyroidism - cinacalcet HCl, draft scope (PDF 27 KB)

(Archive): Hyperparathyroidism - cinacalcet HCl, provisional matrix (PDF 23 KB)